High-flow nasal cannula oxygen in children with bronchiolitis: A randomized controlled trial

Basit Öğe Kaydı
dc.authoridKartal Öztürk, Gökçen/0000-0002-0793-9710
dc.authorscopusid57211344435
dc.authorscopusid57211344272
dc.authorscopusid57194763753
dc.authorscopusid57212220169
dc.authorscopusid9036191300
dc.authorscopusid7004473191
dc.authorwosidKartal Öztürk, Gökçen/AAM-9743-2021
dc.contributor.authorEski, Aykut
dc.contributor.authorOzturk, Gokcen Kartal
dc.contributor.authorTuran, Caner
dc.contributor.authorOzgul, Semiha
dc.contributor.authorGulen, Figen
dc.contributor.authorDemir, Esen
dc.date.accessioned2023-01-12T19:49:56Z
dc.date.available2023-01-12T19:49:56Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractObjective To determine whether high-flow nasal cannula oxygen (HFNCO) provided enhanced respiratory support in bronchiolitis than low-flow oxygen (LFO). Methods We conducted a prospective, randomized controlled trial in children between 1 and 24 months diagnosed with moderate-to-severe bronchiolitis requiring oxygen therapy. Participants received LFO via face mask (6-10 L/min) or HFNCO (2 L/kg/min). Primary outcomes were the time that heart rate (HR) and respiratory rate (RR) return to their normal range for age and the time that baseline clinical respiratory score (CRS) regress to a lower severity score. Secondary outcomes were changes in HR, RR, and CRS over time, length of stay (LOS), duration of oxygen requirement, treatment failure, and adverse event (AE). Results Eighty-seven children were enrolled (48 in LFO; 39 in HFNCO). The time that HR and RR baseline values reached their normal range for age was shorter in HFNCO therapy (2.0 h [1.0-4.0] vs. 12.0 h [2.0-24.0], and 4.0 h [2.0-12.0] vs. 24.0 h [4.0-48.0], respectively; p < 0.001); additionally, the improvement in CRS emerged more quickly in children treated with HFNCO (2.0 h [1.0-4.0] vs. 4.0 h [2.0-24.0]; p = 0.003). While the duration of oxygen requirement (19.0 h [4.0-30.0] vs. 29.5 h [14.0-45.7]; p = 0.009) and treatment failure (3% vs. 21%) was statistically lower in children who received HFNCO, there were no differences in LOS and AE between groups. Conclusion HFNCO may provide enhanced respiratory support with a notable improvement in HR, RR, and CRS than LFO. Comprehensive studies are needed to assess the clinical efficacy of HFNCO therapy.en_US
dc.description.sponsorshipEge University Research Foundation [17-2.1/18]en_US
dc.description.sponsorshipEge University Research Foundation, Grant/Award Number: 17-2.1/18en_US
dc.identifier.doi10.1002/ppul.25893
dc.identifier.endpage1534en_US
dc.identifier.issn8755-6863
dc.identifier.issn1099-0496
dc.identifier.issue6en_US
dc.identifier.pmid35293153en_US
dc.identifier.scopus2-s2.0-85127277473en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1527en_US
dc.identifier.urihttps://doi.org/10.1002/ppul.25893
dc.identifier.urihttps://hdl.handle.net/11454/75961
dc.identifier.volume57en_US
dc.identifier.wosWOS:000773560600001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofPediatric Pulmonologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectbronchiolitisen_US
dc.subjectchildrenen_US
dc.subjectclinical respiratory scoreen_US
dc.subjecthigh-flow nasal cannula oxygenen_US
dc.subjecthypoxiaen_US
dc.subjectVirus-Associated Hospitalizationsen_US
dc.subjectUnited-Statesen_US
dc.subjectTherapyen_US
dc.subjectInfantsen_US
dc.subjectDeliveryen_US
dc.subjectModerateen_US
dc.titleHigh-flow nasal cannula oxygen in children with bronchiolitis: A randomized controlled trialen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu